Non-opposition to a notified concentration

(Case No IV/M.677 — Skanska Fastigheter/Securum Förvaltning)

(96/C 54/03)

(Text with EEA relevance)

On 8 January 1996, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6 (1) (b) of Council Regulation (EEC) No 4064/89 [1]. Third parties showing a sufficient interest can obtain a copy of the decision by making a written request to:

Commission of the European Communities,
Directorate-General for Competition (DG IV),
Directorate B — Merger Task Force,
Avenue de Cortenberg/Kortenberglaan 150,
B-1049 Brussels,
fax number: (32 2) 296 43 01.

[1] OJ No L 395, 30. 12. 1989; Corrigendum: OJ No L 257, 21. 9. 1990, p. 13.

Summary of Community decisions on marketing authorizations in respect of medicinal products from 15 January 1996 to 15 February 1996

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 [1])

(96/C 54/04)

Issuing of a marketing authorization

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community register	Date of notification
14. 2. 1996	Fareston	Ercopharm A/S, Bøgeskovvej 9, DK-3490 Kvistgård	EU/1/96/004/001-002	16. 2. 1996
14. 2. 1996	Cellcept	Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire, AL7 3AY United Kingdom	EU/1/96/005/001-002	15. 2. 1996

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Agency for the Evaluation of Medicinal Products,
7 Westferry Circus, Canary Wharf,
London E14 4HB
United Kingdom.

[1] OJ No L 214, 24. 8. 1993, p. 1.